Literature DB >> 19785973

Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults.

Anthony L Rostain1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19785973     DOI: 10.1007/s11920-009-0064-3

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


× No keyword cloud information.
  3 in total

1.  Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

Authors:  Joseph Biederman; Suma Krishnan; Yuxin Zhang; James J McGough; Robert L Findling
Journal:  Clin Ther       Date:  2007-03       Impact factor: 3.393

2.  Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.

Authors:  Robert L Findling; Ann C Childress; Suma Krishnan; James J McGough
Journal:  CNS Spectr       Date:  2008-07       Impact factor: 3.790

3.  Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.

Authors:  Joseph Biederman; Samuel W Boellner; Ann Childress; Frank A Lopez; Suma Krishnan; Yuxin Zhang
Journal:  Biol Psychiatry       Date:  2007-07-12       Impact factor: 13.382

  3 in total
  1 in total

1.  Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Xavier Castells; Lídia Blanco-Silvente; Ruth Cunill
Journal:  Cochrane Database Syst Rev       Date:  2018-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.